ABSTRACT
OBJECTIVES: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir. METHODS: From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir. Each of these patients was matched with three patients who continued to take their first-line cART regimen, on the basis of gender, age, CD4 cell count, VL, date of cART initiation and the duration of VL undetectability. Time to virological failure (VF) was analysed with Kaplan-Meier curves and Cox models. RESULTS: The 12 month probabilities of VF were 3.7% and 5.7% in non-switch and switch patients, respectively, and 3.9%, 7.2% and 9.0% in patients switching to efavirenz-, nevirapine- and abacavir-containing cART, respectively. After adjustment, only patients switching to abacavir-containing cART had a higher risk of VF than non-switch patients (adjusted hazard ratio, 1.99; 95% confidence interval, 1.05-3.79). CONCLUSIONS: Switching from a virologically successful first-line boosted PI-containing cART regimen to a non-nucleoside reverse transcriptase inhibitor-containing cART regimen containing either efavirenz or nevirapine is virologically safe, while switching to abacavir-containing cART should be avoided.
Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV/isolation & purification , Viral Load , Adult , Alkynes , Benzoxazines/administration & dosage , Cohort Studies , Cyclopropanes , Dideoxynucleosides/administration & dosage , Female , HIV Protease Inhibitors/administration & dosage , Humans , Male , Nevirapine/administration & dosage , Prospective Studies , Treatment OutcomeABSTRACT
The influence of HAART on the survival of patients with AIDS-related lymphoma (ARL) was evaluated. A retrospective analysis of 73 HIV-1-infected patients with proven ARL diagnosed between 1992 and 2000 was conducted. Patients received uniformly the same chemotherapy regimen according to CD4 cell counts at NHL diagnosis:, patients with CD4 cells below or above 100 cells x 10(6)/liter received CHOP or ACVBP regimens, respectively. Event-free survival (EFS) and survival were estimated by the Kaplan-Meir method and a Cox model was used to evaluate the effect of different variables on survival. At diagnosis of ARL, the median age was 37 years and 22 patients (30%) had prior AIDS-defining events. Median CD4 cell count was 99 x 10(6)/liter. The median follow-up was 60 months. Ann Arbor stage 3-4 was noted in 60 patients (82%) and bone marrow or meningeal involvement was present in 13 (17%) and 12 (16%) patients, respectively. Two groups were identified: group 1 (n = 38) included patients who had never received HAART and group 2 (n = 35) included those who received HAART either before the diagnosis or following ARL. There was no statistical significant differences in lymphoma extensive stage, presence of B symptoms, meningeal involvement, CD4 cell count at diagnosis, prior AIDS events, or chemotherapy regimens between the two groups. Median survival (MS) of the whole cohort of patients was 8 months. Estimated EFS was significantly higher (30 months) in group 2 compared to group 1 (6.1 months) (p = 0.03). In the multivariate Cox model HAART has an independent significant effect on EFS (p = 0.0085). No influence on outcome was found for other variables except for prior AIDS and bone marrow involvement. HAART has significantly improved the survival and EFS in patients with ARL, independently of chemotherapy regimen.
Subject(s)
Antiretroviral Therapy, Highly Active , Lymphoma, AIDS-Related/mortality , Adult , CD4 Lymphocyte Count , Female , Humans , Lymphoma, AIDS-Related/immunology , Male , Prognosis , Retrospective StudiesABSTRACT
BACKGROUND: In vitro exposure to benzyl benzoate (25 p. 100) kills Sarcoptes scabiei within three hours. The aim of our study was to determine in vivo elimination of Sarcopte scabiei with a benzyl benzoate-sulfiram association. METHODS: Medical charts of patients hospitalized for disseminated scabies from 1993 to 1999 were reviewed retrospectively. The diagnosis of scabies was confirmed by microscopic determination. Parasitological examinations were conducted every day or every two days until negative results. Patients were treated by successive applications of benzyl benzoate until parasitological cure. RESULTS: Twenty patients were included in the study. The median delay of parasitological cure was seven days. After 15 days, 95 p. 100 of patients were cured. Two cutaneous side-effects were reported. DISCUSSION: Despite immediate in vitro efficacy, benzyl benzoate action is delayed in vivo. The time of parasitological negativation after one application of benzyl benzoate is unknown. Therefore, it is not currently possible to determine whether our therapeutic regimen was excessive or not.
Subject(s)
Benzoates/pharmacokinetics , Benzoates/therapeutic use , Disulfiram/analogs & derivatives , Disulfiram/pharmacokinetics , Disulfiram/therapeutic use , Insecticides/pharmacokinetics , Insecticides/therapeutic use , Scabies/drug therapy , Aged , Drug Therapy, Combination , Female , Humans , Male , Severity of Illness IndexSubject(s)
Abscess/microbiology , Acquired Immunodeficiency Syndrome/complications , Escherichia coli Infections/etiology , Neck Pain/microbiology , Spinal Cord Diseases/microbiology , Spinal Cord/microbiology , Abscess/pathology , Abscess/physiopathology , Anti-Bacterial Agents/therapeutic use , Cervical Vertebrae , Drug Therapy, Combination , Escherichia coli Infections/pathology , Escherichia coli Infections/physiopathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neck Pain/pathology , Neck Pain/physiopathology , Prognosis , Spinal Cord/pathology , Spinal Cord/physiopathology , Spinal Cord Diseases/pathology , Spinal Cord Diseases/physiopathology , Treatment OutcomeABSTRACT
PURPOSE: To describe the clinical features in HIV-1-infected patients treated with protease inhibitors (PIs) or not, and to determine factors related to occurrence of lipodystrophy (LD). METHOD: We performed a cross-sectional analysis of 685 treated HIV-1-infected patients that were routinely followed in 6 Paris hospital centers between January and May 1999. Demographic data, familial and personal vascular risk factors, history of antiretroviral treatment, HIV plasma viral load, CD4 cell count, and metabolic data were collected. Clinical examination was based on an assessment of changes in abdominal, dorso-cervical, and breast girth and wasting of the limbs, face, and skin as quoted by the clinician. RESULTS: The mean age at inclusion in the study was 38 years; 29.5% were women. At study assessment, 77.5% of patients were PI-treated and 22.5% had never received a PI. LD was observed in 403 (58.8%) patients, of whom 340 were currently receiving a PI and 63 had never received a PI. More than half of the lipodystrophic patients had a mixed form (53.9%), while 25.3% were classified as exclusive lipoatrophic and 20.8% as exclusive hypertrophic. In multivariate analysis, older age, duration of antiretroviral treatment (ART), antiretroviral combinations including stavudine, antiretroviral combinations including a PI, AIDS status, and a low HIV RNA were independently associated with occurrence of LD. CONCLUSION: LD is frequently observed in PI-treated patients, but it is also observed in patients receiving an ART regimen without PIs. Our study suggests different underlying mechanisms, because immunovirological response to treatment as well as certain therapies were linked to the occurrence of LD. This hypothesis would be best clarified in a large prospective cohort of naive patients.
Subject(s)
Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , Lipodystrophy/chemically induced , Lipodystrophy/epidemiology , Reverse Transcriptase Inhibitors/adverse effects , Adult , Cross-Sectional Studies , Drug Therapy, Combination , Female , HIV-1/isolation & purification , Humans , Male , RNA, Viral/blood , Risk FactorsSubject(s)
Anti-HIV Agents/adverse effects , Edema/chemically induced , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Inflammation/chemically induced , Leg/pathology , Pyrimidinones/adverse effects , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/adverse effects , Female , HIV Protease Inhibitors/therapeutic use , Humans , Lopinavir , Male , Middle Aged , Pyrimidinones/therapeutic useABSTRACT
NEW AGENTS: Among new treatments used for infectious dermatology diseases, new agents for genital herpes, valaciclovir and famciclovir, have greatly simplified therapeutic schemes. Cidofovir has also been shown to be effective against aciclovir-resistant cutaneous and mucosal herpetic lesions and for the treatment of molluscum contagiosum. NEW ADMINISTRATION ROUTES: For genital papillomavirus infections, trials using systemic or intralesional administered interferon have not provided conclusive evidence but imiquimode appears to be quite promising. Itaconazole and fluconazole are effective for onchomycoses. NEW POSSIBILITIES: Ivermectine is effective against scabies, but must be reserved for particularly severe forms. Finally, the emergence of Neisseria gonorrhoeae strains resistant to fluoroquinolones is disquieting.
Subject(s)
Skin Diseases, Infectious/drug therapy , Antifungal Agents/therapeutic use , Antiviral Agents/therapeutic use , Dermatomycoses/drug therapy , Herpes Simplex/drug therapy , Humans , Molluscum Contagiosum/drug therapy , Papillomaviridae , Papillomavirus Infections/drug therapy , Skin Diseases, Viral/drug therapy , Tumor Virus Infections/drug therapyABSTRACT
BACKGROUND: Trichosporon beigelii, causal agent of white piedra can cause disseminated infection in immunodepressed subjects. Systemic infections due to this pathogen have been reported mainly in neutropenic patients and rarely in AIDS patients. CASE REPORT: A 36-year-old HIV+ man from Senegal was hospitalized for fever and meningoencephalitis associated with skin lesions. T. beigelii was isolated from skin biopsies and cerebrospinal fluid cultures. The patients was treated with amphotericin B with regression of the skin lesions. The diagnosis of disseminated T. beigelii infection was retained. DISCUSSION: Disseminated T. beigelii infections are known to occur in immunodepressed subjects, especially in case of neutropenia. In our patient, the presence of two proven localizations (meninges and skin) and the favorable outcome with amphotericin B favored disseminated infection. The good response to treatment can probably be explained by the absence of neutropenia. Skin lesions are frequent, usually occurring as disseminated papulae or purpural nodules. Pathology examination and skin biopsy culture can provide rapid diagnosis allowing appropriate treatment.